A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb20717 in Subjects With Selected Advanced Solid Tumors
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Vudalimab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Acronyms DUET-2
- Sponsors Xencor
- 29 Nov 2022 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 28 Feb 2023 to 30 Nov 2022.
- 19 Jul 2022 Status changed from recruiting to active, no longer recruiting.